Colorado Biosimilars Bill Closely Mirrors Compromise Substitution Language
Thursday, January 29, 2015
Source: FDA News
Colorado lawmakers have introduced a biosimilar substitution bill that closely mirrors at least one aspect of compromise language unveiled by industry leaders last month — elimination of prescriber notification in favor of entering a switch into an electronic database.
Under the bill, pharmacists will only notify prescribers that they’ve switched a patient from brand to biosimilar if no database is available to make note of a swap. Otherwise, the prescribing physician will only learn that a patient has been switched if they check the database.
The legislation was introduced into a state Senate committee two weeks ago.